Northwest Biotherapeutics (NWBO) Total Debt (2010 - 2026)

Northwest Biotherapeutics' Total Debt history runs 17 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• In Q1 2026, Total Debt fell 56.47% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $7.2 million (down 56.47% YoY), while the FY2025 annual figure was $21.7 million, down 1.02% from the prior year.
• Total Debt for Q1 2026 stood at $7.2 million, down from $21.7 million in the prior quarter.
• The five-year high for Total Debt was $29.9 million in Q3 2024, with the low at $7.2 million in Q1 2026.
• The 5-year median for Total Debt is $21.7 million (2025), against an average of $20.9 million.
• The sharpest annual moves came in 2023 and 2026: Total Debt soared 101.24% in 2023, then sank 56.47% in 2026.
• Northwest Biotherapeutics' Total Debt stood at $14.7 million in 2022, then jumped by 101.24% to $29.5 million in 2023, then dropped by 25.51% to $22.0 million in 2024, then declined by 1.02% to $21.7 million in 2025, then sank by 66.88% to $7.2 million in 2026.
• Business Quant data shows NWBO's Total Debt at $7.2 million in Q1 2026, $21.7 million in Q4 2025, and $16.9 million in Q3 2025.